C-Myc Alterations Confer Therapeutic Response and Acquired Resistance to C-Met Inhibitors in MET-addicted Cancers.

Aijun Shen,Lu Wang,Min Huang,Jingya Sun,Yi Chen,Yan-Yan Shen,Xinying Yang,Xin Wang,Jian Ding,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.can-14-2743

IF: 11.2

2015-01-01

Cancer Research

Abstract:AbstractUse of kinase inhibitors in cancer therapy leads invariably to acquired resistance stemming from kinase reprogramming. To overcome the dynamic nature of kinase adaptation, we asked whether a signal-integrating downstream effector might exist that provides a more applicable therapeutic target. In this study, we reported that the transcriptional factor c-Myc functions as a downstream effector to dictate the therapeutic response to c-Met inhibitors in c-Met–addicted cancer and derived resistance. Dissociation of c-Myc from c-Met control, likely overtaken by a variety of reprogrammed kinases, led to acquisition of drug resistance. Notably, c-Myc blockade by RNA interference or pharmacologic inhibition circumvented the acquired resistance to c-Met inhibition. Combining c-Myc blockade and c-Met inhibition in MET-amplified patient-derived xenograft mouse models heightened therapeutic activity. Our findings offer a preclinical proof of concept for the application of c-Myc–blocking agents as a tactic to thwart resistance to kinase inhibitors. Cancer Res; 75(21); 4548–59. ©2015 AACR.